Oncolytics Biotech (ONCY) Liabilities and Shareholders Equity (2009 - 2025)

Oncolytics Biotech (ONCY) has 17 years of Liabilities and Shareholders Equity data on file, last reported at $7.6 million in Q4 2025.

• On a quarterly basis, Liabilities and Shareholders Equity fell 47.53% year-over-year to $7.6 million in Q4 2025; TTM through Dec 2025 was $46.7 million, a 42.72% decrease from a year earlier, with the FY2025 full-year figure at $7.6 million, down 48.58% from the prior year.
• Liabilities and Shareholders Equity for Q4 2025 stood at $7.6 million, down from $10.9 million in the prior quarter.
• Over the last five years, Liabilities and Shareholders Equity for ONCY reached as high as $45.8 million in Q2 2021 and fell as low as $7.6 million in Q4 2025.
• Historically, Liabilities and Shareholders Equity has averaged $26.6 million across 5 years, with a median of $26.8 million in 2022.
• Across the five-year window, Liabilities and Shareholders Equity soared 38.16% in 2021 and slumped 49.32% in 2024, its largest moves.
• Year by year, Liabilities and Shareholders Equity stood at $36.4 million in 2021, then fell by 24.44% to $27.5 million in 2022, then gained by 3.67% to $28.5 million in 2023, then slumped by 49.32% to $14.5 million in 2024, then sank by 47.53% to $7.6 million in 2025.
• Per Business Quant data, the three most recent Liabilities and Shareholders Equity figures were $7.6 million in Q4 2025, $10.9 million in Q3 2025, and $14.4 million in Q2 2025.